Nearly two-thirds of patients with colorectal cancer indicate financial burdens
the ONA take:
According to a new study published in the journal Medical Care, researchers at the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan, have found that about 62% of patients with colorectal cancer report some form of financial burden as a result of their cancer treatment.
For the study, the researchers surveyed 956 patients who had been treated for stage 3 colorectal cancer. Based on seven questions about financial burden, 29% indicated one to two areas of burden, 23% indicated three to four areas of burden, and 9% indicated 5 or more burdens. The questions referred to whether the patients had used savings, borrowed money, missed bill payments, or cut back spending on items like food, clothing, or activities.
The researchers found that the financial burden was highest among patients who received chemotherapy. In addition, younger, working patients with low-incomes were more likely to experience financial burdens as they could not afford to take time off from their jobs.
Their findings suggest that policy changes should be urged to allow support for patients who need time off from work to receive cancer care. The researchers recommend that patients speak with their physicians about their financial concerns.
About 62% of patients with colorectal cancer report some form of financial burden.
Nearly two-thirds of patients treated for colorectal cancer reported some measure of financial burden due to their treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. The burden was greatest among patients who received chemotherapy and among younger patients who worked in low-paying jobs.
The study surveyed 956 patients who had been treated for stage 3 colorectal cancer. Among this group, chemotherapy is known to increase survival by up to 20 percent and is routinely recommended following surgery.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|